2030年までの欧州抗体薬物複合体市場予測 - 地域分析 - 技術別（切断可能リンカーおよび非切断可能リンカー）、用途別（血液がん、乳がん、卵巣がん、尿路上皮がんなど）、流通チャネル別（病院薬局、小売）薬局、オンライン薬局)

Table of Content

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Antibody Drug Conjugates Market - Key Industry Dynamics

4.1 Key Market Drivers:

4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates

4.1.2 Rising Incidences of Cancer Cases

4.1.3 Increasing FDA Approvals for ADCs

4.2 Market Restraints

4.2.1 High Cost of ADCs Development and Commercialization

4.3 Market Opportunities

4.3.1 Increasing Investments to Develop ADCs

4.4 Market Trends

4.4.1 Escalating Pipeline of ADCs

4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - Europe Market Analysis

5.1 Europe Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

6.1 Overview

6.2 Europe Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)

6.3 Cleavable Linker

6.3.1 Overview

6.3.2 Cleavable Linker: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

6.4 Non-cleavable Linker

6.4.1 Overview

6.4.2 Non-cleavable Linker: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

7.1 Overview

7.2 Europe Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)

7.3 Blood Cancer

7.3.1 Overview

7.3.2 Blood Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Breast Cancer

7.4.1 Overview

7.4.2 Breast Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Ovarian Cancer

7.5.1 Overview

7.5.2 Ovarian Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.6 Urothelial Cancer

7.6.1 Overview

7.6.2 Urothelial Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7.7 Others

7.7.1 Overview

7.7.2 Others: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview

8.2 Europe Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

8.3 Hospital Pharmacies

8.3.1 Overview

8.3.2 Hospital Pharmacies: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Retail Pharmacies

8.4.1 Overview

8.4.2 Retail Pharmacies: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8.5 Online Pharmacies

8.5.1 Overview

8.5.2 Online Pharmacies: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Antibody Drug Conjugates Market - Country Analysis

9.1 Europe Antibody Drug Conjugates Market, Revenue and Forecast To 2030

9.1.1 Overview

9.1.2 Europe Antibody Drug Conjugates Market Breakdown, by Country - Revenue (2022) (US$ Million)

9.1.3 Europe: Antibody Drug Conjugates Market, by Country

9.1.3.1 UK

9.1.3.1.1 Overview

9.1.3.1.2 UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.1.3 UK: Antibody Drug Conjugates Market, by Technology

9.1.3.1.4 UK: Antibody Drug Conjugates Market, by Application

9.1.3.1.5 UK: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.2 Germany

9.1.3.2.1 Overview

9.1.3.2.2 Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.2.3 Germany: Antibody Drug Conjugates Market, by Technology

9.1.3.2.4 Germany: Antibody Drug Conjugates Market, by Application

9.1.3.2.5 Germany: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.3 France

9.1.3.3.1 Overview

9.1.3.3.2 France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.3.3 France: Antibody Drug Conjugates Market, by Technology

9.1.3.3.4 France: Antibody Drug Conjugates Market, by Application

9.1.3.3.5 France: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.4 Italy

9.1.3.4.1 Overview

9.1.3.4.2 Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.4.3 Italy: Antibody Drug Conjugates Market, by Technology

9.1.3.4.4 Italy: Antibody Drug Conjugates Market, by Application

9.1.3.4.5 Italy: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.5 Spain

9.1.3.5.1 Overview

9.1.3.5.2 Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.5.3 Spain: Antibody Drug Conjugates Market, by Technology

9.1.3.5.4 Spain: Antibody Drug Conjugates Market, by Application

9.1.3.5.5 Spain: Antibody Drug Conjugates Market, by Distribution Channel

9.1.3.6 Rest of Europe

9.1.3.6.1 Overview

9.1.3.6.2 Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

9.1.3.6.3 Rest of Europe: Antibody Drug Conjugates Market, by Technology

9.1.3.6.4 Rest of Europe: Antibody Drug Conjugates Market, by Application

9.1.3.6.5 Rest of Europe: Antibody Drug Conjugates Market, by Distribution Channel

10. Antibody Drug Conjugates Market-Industry Landscape

10.1 Overview

10.2 Organic Growth Strategies

10.2.1 Overview

10.3 Inorganic Growth Strategies

10.3.1 Overview

10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

11.1 ADC Therapeutics SA

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Pfizer Inc

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Hoffmann-La Roche Ltd

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 ImmunoGen, Inc.

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 GSK Plc

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Gilead Sciences Inc

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 AstraZeneca Plc

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 Astellas Pharma Inc

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

11.9 Takeda Pharmaceutical Co Ltd

11.9.1 Key Facts

11.9.2 Business Description

11.9.3 Products and Services

11.9.4 Financial Overview

11.9.5 SWOT Analysis

11.9.6 Key Developments

12. Appendix

12.1 About Us

12.2 Glossary of Terms

List of Tables

Table 1. Europe Antibody Drug Conjugates Market Segmentation

Table 2. New Cancer Cases Worldwide, in 2020

Table 3. List of FDA-Approved ADCs

Table 4. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 5. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 6. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 7. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 8. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 9. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 10. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 11. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 12. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 13. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 14. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 15. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 16. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 17. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 18. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 19. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology

Table 20. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application

Table 21. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel

Table 22. Recent Organic Growth Strategies in Antibody Drug Conjugates Market

Table 23. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market

Table 24. Glossary of Terms, Antibody Drug Conjugates Market

List of Figures

Figure 1. Europe Antibody Drug Conjugates Market Segmentation, By Country

Figure 2. Key Insights

Figure 3. Europe Antibody Drug Conjugates Market - Key Industry Dynamics

Figure 4. Impact Analysis of Drivers and Restraints

Figure 5. Europe Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

Figure 6. Europe Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)

Figure 7. Cleavable Linker: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Non-Cleavable Linker: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Europe Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)

Figure 10. Blood Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Breast Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Ovarian Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Urothelial Cancer: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Others: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 15. Europe Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

Figure 16. Hospital Pharmacies: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Retail Pharmacies: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Online Pharmacies: Europe Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

Figure 19. Europe Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)

Figure 20. Europe: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)

Figure 21. UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 22. Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 23. France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 24. Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 25. Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

Figure 26. Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)

1. ADC Therapeutics SA
2. Pfizer Inc
3. Hoffmann-La Roche Ltd
4. ImmunoGen, Inc
5. GSK Plc
6. Gilead Sciences Inc
7. AstraZeneca Plc
8. Astellas Pharma Inc
9. Takeda Pharmaceutical Co Ltd

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe antibody drug conjugates market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in Europe antibody drug conjugates market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution